Cdc42 Cancer Research Results
Cdc42, Cdc42cdc2: Click to Expand ⟱
| Source: |
| Type: |
Cdc42 is a small GTPase that plays a crucial role in various cellular processes, including cell growth, migration, and survival.
High Cdc2 expression has been associated with poor prognosis and reduced overall survival in cancer patients.
Low Cdc2 expression has been associated with good prognosis and improved overall survival in cancer patients.
|
Scientific Papers found: Click to Expand⟱
eff↑, newly developed boron-containing compounds have already demonstrated highly promising activities
*toxicity↓, Boronic acid/ester has been successfully incorporated into cancer treatments and therapy mainly due to its remarkable oxophilicity and low toxicity levels in the body
ROS↑, can trigger tumour microenvironmental abnormalities such as high levels of reactive oxygen species (ROS) and overexpressed enzymes
LAT↓, boron accumulation were observed to counterpart LAT-1 expression in a bone metastasis model of breast cancer
AntiCan↑, high concentration of boron in males reduces the probability of prostate cancer by 54% compared to males with low boron concentrations
AR↓, bortezomib
PSMB5↓, bortezomib
IGF-1↓, insulin-like growth factor 1 (IGF-1) in tumours was markedly reduced by boric acid.
PSA↓, exposure to both low-and high-dose boron supplementation, prostate-specific antigen (PSA) levels dropped by an average of 87%, while tumour size declined by an average of 31.5%
TumVol↓,
eff↑, phenylboronic acid is a more potent inhibitor than boric acid in targeting metastatic and proliferative properties of prostate cancer cells
Rho↓, RhoA, Rac1
Cdc42↓,
Ca+2↓, ER Ca+2 depletion occurred after the treatment of DU-145 prostate cancer cells with the physiological concentrations of boric acid
eff↑, boric acid (BA), sodium pentaborate pentahydrate (NaB), and sodium perborate tetrahydrate (SPT) against SCLC cell line using DMS-114 cells
| - |
in-vitro, |
Pca, |
DU145 |
|
|
|
- |
in-vitro, |
Nor, |
RWPE-1 |
|
|
|
Rho↓, RhoA, but not in normal RWPE-1 prostate cells
Rac1↓, but not in normal RWPE-1 prostate cells
Cdc42↓, but not in normal RWPE-1 prostate cells
*eff↑, RhoA, Rac1, and Cdc42 activity is decreased in prostate cancer cells but not in normal prostate cells.
RadioS↑, it can be used as an adjuvant to radio-chemotherapy and helps to ameliorate cancer complications
ChemoSen↑,
chemoP↑,
*lipid-P↓, ↓LPO, ↑CAT, ↑SOD, ↑GPx, ↑GST, ↑GSH, ↓TNF-α, ↓IL-1β, ↓Caspase-3, ↑IL-10
*Catalase↑,
*SOD↑,
*GPx↑,
*GSTs↑,
*GSH↑,
*TNF-α↓,
*IL1β↓,
*Casp3↓,
*IL10↑,
NRF2↓, Lung cancer model ↓Nrf2, ↓HO-1, ↓NQO1, ↓GSH
HO-1↓,
NQO1↓,
GSH↓,
MET↓, Lung cancer model ↓MET, ↓p-MET, ↓p-Akt, ↓HGF
p‑MET↓,
p‑Akt↓,
HGF/c-Met↓,
NF-kB↓, Lung cancer model ↓NF-κB, ↓Bcl-XL, ↓MnSOD, ↑Caspase-8, ↑Caspase-3, ↑PARP
Bcl-2↓,
SOD2↓,
Casp8↑,
Casp3↑,
PARP↑,
MAPK↓, LLC-induced BCP mouse model ↓p38 MAPK, ↓GFAP, ↓IBA1, ↓NLRP3, ↓ASC, ↓Caspase1, ↓IL-1β
NLRP3↓,
ASC↓,
Casp1↓,
IL6↓, Lung cancer model ↓TNF‑α, ↓IL‑6, ↓MuRF1, ↓Atrogin-1, ↓IKKβ, ↓p‑p65, ↓p-p38
IKKα↓,
p‑p65↓,
p‑p38↑,
MMP2↓, Lung cancer model ↓MMP-2, ↓ICAM-1, ↓EGFR, ↓p-PI3K, ↓p-Akt
ICAM-1↓,
EGFR↑,
p‑PI3K↓,
E-cadherin↓, Lung cancer model ↑E-cadherin, ↑ZO-1, ↓N-cadherin, ↓Claudin-1, ↓β-Catenin, ↓Snail, ↓Vimentin, ↓Integrin β1, ↓FAK
ZO-1↑,
N-cadherin↓,
CLDN1↓,
β-catenin/ZEB1↓,
Snail↓,
Vim↑,
ITGB1↓,
FAK↓,
p‑Src↓, Lung cancer model ↓p-FAK, ↓p-Src, ↓Rac1, ↓Cdc42, ↓RhoA
Rac1↓,
Cdc42↓,
Rho↓,
PCNA↓, Lung cancer model ↓Cyclin B1, ↑p21, ↑p-Cdc2, ↓Vimentin, ↓MMP9, ↑E-cadherin, ↓AIM2, ↓Pro-caspase-1, ↓Caspase-1 p10, ↓Pro-IL-1β, ↓IL-1β, ↓PCNA
Tyro3↓, Lung cancer model ↓TAM RTKs, ↓Tyro3, ↓Axl, ↓MerTK, ↑p21
AXL↓,
CEA↓, B(a)P induced lung carcinogenesis ↓CEA, ↓NSE, ↑SOD, ↑CAT, ↑GPx, ↑GR, ↑GST, ↑GSH, ↑Vitamin E, ↑Vitamin C, ↓PCNA, ↓CYP1A1, ↓NF-kB
NSE↓,
SOD↓,
Catalase↓,
GPx↓,
GSR↓,
GSTs↓,
GSH↓,
VitE↓,
VitC↓,
CYP1A1↓,
cFos↑, Lung cancer model ↓Claudin-2, ↑p-ERK1/2, ↑c-Fos
AR↓, ↓Androgen receptor
AIF↑, Lung cancer model ↑Apoptosis-inducing factor protein
p‑STAT6↓, ↓p-STAT6, ↓Arginase-1, ↓MRC1, ↓CCL2
p‑MDM2↓, Lung cancer model ↓p-PI3K, ↓p-Akt, ↓p-MDM2, ↑p-P53, ↓Bcl-2, ↑Bax
NOTCH1↓, Lung cancer model ↑Bax, ↑Cleaved-caspase 3, ↓Bcl2, ↑circ_0000190, ↓miR-130a-3p, ↓Notch-1, ↓Hes-1, ↓VEGF
VEGF↓,
H3↓, Lung cancer model ↑Caspase 3, ↑Caspase 7, ↓H3 and H4 HDAC activities
H4↓,
HDAC↓,
SIRT1↓, Lung cancer model ↑Bax/Bcl-2, ↓Sirt1
ROS↑, Lung cancer model ↓NF-kB, ↑JNK, ↑Caspase 3, ↑PARP, ↑ROS, ↓SOD
DR5↑, Lung cancer model ↑Caspase-8, ↑Caspase-3, ↑Caspase-9, ↑DR5, ↑p-Drp1, ↑Cytochrome c, ↑p-JNK
Cyt‑c↑,
p‑JNK↑,
PTEN↓, Lung cancer model 1/5/10/30/50/80/100 μmol/L ↑Cleaved caspase-3, ↑PARP, ↑Bax, ↓Bcl-2, ↓EGFR, ↓PI3K/Akt/PTEN/mTOR, ↓CD34, ↓PCNA
mTOR↓,
CD34↓,
FasL↑, Lung cancer model ↑DR 4, ↑FasL, ↑Fas receptor, ↑Bax, ↑Bad, ↓Bcl-2, ↑Cytochrome c, ↓XIAP, ↑p-eIF2α, ↑CHOP, ↑p-JNK, ↑LC3II
Fas↑,
XIAP↓,
p‑eIF2α↑,
CHOP↑,
LC3II↑,
PD-1↓, Lung cancer model ↓PD-L1, ↓STAT3, ↑IL-2
STAT3↓,
IL2↑,
EMT↓, Luteolin exerts anticancer activity by inhibiting EMT, and the possible mechanisms include the inhibition of the EGFR-PI3K-AKT and integrin β1-FAK/Src signaling pathways
cachexia↓, luteolin could be a potential safe and efficient alternative therapy for the treatment of cancer cachexi
BioAv↑, A low-energy blend of castor oil, kolliphor and polyethylene glycol 200 increases the solubility of luteolin by a factor of approximately 83
*Half-Life↝, ats administered an intraperitoneal injection of luteolin (60 mg/kg) absorbed it rapidly as well, with peak levels reached at 0.083 h (71.99 ± 11.04 μg/mL) and a prolonged half-life (3.2 ± 0.7 h)
*eff↑, Luteolin chitosan-encapsulated nano-emulsions increase trans-nasal mucosal permeation nearly 6-fold, drug half-life 10-fold, and biodistribution of luteolin in brain tissue 4.4-fold after nasal administration
Showing Research Papers: 1 to 3 of 3
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
Catalase↓, 1, CYP1A1↓, 1, GPx↓, 1, GSH↓, 2, GSR↓, 1, GSTs↓, 1, HO-1↓, 1, NQO1↓, 1, NRF2↓, 1, ROS↑, 2, SOD↓, 1, SOD2↓, 1, VitC↓, 1, VitE↓, 1,
Mitochondria & Bioenergetics ⓘ
AIF↑, 1, XIAP↓, 1,
Core Metabolism/Glycolysis ⓘ
LAT↓, 1, PSMB5↓, 1, SIRT1↓, 1,
Cell Death ⓘ
p‑Akt↓, 1, Bcl-2↓, 1, Casp1↓, 1, Casp3↑, 1, Casp8↑, 1, Cyt‑c↑, 1, DR5↑, 1, Fas↑, 1, FasL↑, 1, HGF/c-Met↓, 1, p‑JNK↑, 1, MAPK↓, 1, p‑MDM2↓, 1, p‑p38↑, 1,
Transcription & Epigenetics ⓘ
H3↓, 1, H4↓, 1,
Protein Folding & ER Stress ⓘ
CHOP↑, 1, p‑eIF2α↑, 1,
Autophagy & Lysosomes ⓘ
LC3II↑, 1,
DNA Damage & Repair ⓘ
PARP↑, 1, PCNA↓, 1,
Proliferation, Differentiation & Cell State ⓘ
CD34↓, 1, cFos↑, 1, EMT↓, 1, HDAC↓, 1, IGF-1↓, 1, mTOR↓, 1, NOTCH1↓, 1, p‑PI3K↓, 1, PTEN↓, 1, p‑Src↓, 1, STAT3↓, 1, p‑STAT6↓, 1,
Migration ⓘ
AXL↓, 1, Ca+2↓, 1, Cdc42↓, 3, CEA↓, 1, CLDN1↓, 1, E-cadherin↓, 1, FAK↓, 1, ITGB1↓, 1, MET↓, 1, p‑MET↓, 1, MMP2↓, 1, N-cadherin↓, 1, Rac1↓, 2, Rho↓, 3, Snail↓, 1, Tyro3↓, 1, Vim↑, 1, ZO-1↑, 1, β-catenin/ZEB1↓, 1,
Angiogenesis & Vasculature ⓘ
EGFR↑, 1, VEGF↓, 1,
Immune & Inflammatory Signaling ⓘ
ASC↓, 1, ICAM-1↓, 1, IKKα↓, 1, IL2↑, 1, IL6↓, 1, NF-kB↓, 1, p‑p65↓, 1, PD-1↓, 1, PSA↓, 1,
Protein Aggregation ⓘ
NLRP3↓, 1,
Hormonal & Nuclear Receptors ⓘ
AR↓, 2,
Drug Metabolism & Resistance ⓘ
BioAv↑, 1, ChemoSen↑, 1, eff↑, 3, RadioS↑, 1,
Clinical Biomarkers ⓘ
AR↓, 2, CEA↓, 1, EGFR↑, 1, IL6↓, 1, NSE↓, 1, PSA↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, cachexia↓, 1, chemoP↑, 1, TumVol↓, 1,
Total Targets: 98
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
Catalase↑, 1, GPx↑, 1, GSH↑, 1, GSTs↑, 1, lipid-P↓, 1, SOD↑, 1,
Cell Death ⓘ
Casp3↓, 1,
Immune & Inflammatory Signaling ⓘ
IL10↑, 1, IL1β↓, 1, TNF-α↓, 1,
Drug Metabolism & Resistance ⓘ
eff↑, 2, Half-Life↝, 1,
Functional Outcomes ⓘ
toxicity↓, 1,
Total Targets: 13
Scientific Paper Hit Count for: Cdc42, Cdc42cdc2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:880 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page